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ORIGINAL ARTICLE BACTERIOLOGYNasal carriers are more likely to acquire exogenous Staphylococcus aureus
strains than non-carriersH. Ghasemzadeh-Moghaddam1,2, V. Neela1, W. van Wamel3, R. A. Hamat1, M. nor Shamsudin1,4, N. Suhaila Che Hussin5,
M. N. Aziz5, M. S. Mohammad Haspani6, A. Johar7, S. Thevarajah7, M. Vos3 and A. van Belkum3,8
1) Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor,
Malaysia, 2) Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran, 3) Department of Medical Microbiology and Infectious Diseases,
Erasmus MC, Rotterdam, The Netherlands, 4) Marine Science Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia, 5) Pathology
Laboratories, 6) Department of Neurosurgery, 7) Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia and 8) bioMérieux, R&D
Microbiology, La Balme les Grottes, FranceAbstractWeperformed a prospective observational study in a clinical setting to test the hypothesis that prior colonization by a Staphylococcus aureus strain
would protect, by colonization interference or other processes, against de novo colonization and, hence, possible endo-infections by newly
acquired S. aureus strains. Three hundred and six patients hospitalized for >7 days were enrolled. For every patient, four nasal swabs (days 1,
3, 5, and 7) were taken, and patients were identiﬁed as carriers when a positive nasal culture for S. aureus was obtained on day 1 of
hospitalization. For all patients who acquired methicillin-resistant S. aureus (MRSA) or methicillin-susceptible S. aureus via colonization and/
or infection during hospitalization, strains were collected. We note that our study may suffer from false-negative cultures, local problems
with infection control and hospital hygiene, or staphylococcal carriage at alternative anatomical sites. Among all patients, 22% were prior
carriers of S. aureus, including 1.9% whom carried MRSA upon admission. The overall nasal staphylococcal carriage rate among dermatology
patients was signiﬁcantly higher than that among neurosurgery patients (n = 25 (55.5%) vs. n = 42 (16.1%), p 0.005). This conclusion held
when the carriage deﬁnition included individuals who were nasal culture positive on day 1 and day 3 of hospitalization (p 0.0001). All MRSA
carriers were dermatology patients. There was signiﬁcantly less S. aureus acquisition among non-carriers than among carriers during
hospitalization (p 0.005). The mean number of days spent in the hospital before experiencing MRSA acquisition in nasal carriers was 5.1,
which was signiﬁcantly lower than the score among non-carriers (22 days, p 0.012). In conclusion, we found that nasal carriage of S. aureus
predisposes to rather than protects against staphylococcal acquisition in the nose, thereby refuting our null hypothesis.
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p://dx.doi.org/10.1016/j.cmi.2015.07.006IntroductionThe recent introduction of metagenomic technologies has
highlighted the great diversity of bacterial species that live in or
on the human body. These bacteria play an important role in
balancing our health status. However, this natural balance may
be disturbed, and some species can transform from colonizers
into invasive pathogens. The causes of such changes are ill-ious Diseases. Published by Elsevier Ltd. All rights reserved
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inﬂuential, as are bacterial interspecies interactions. Certain
species may preclude the presence of others, and the dynamics
of such interactions may be important in homeostasis. Staphy-
lococcus aureus is one of the best-known human (nasal) colo-
nizers that is also very capable of pathogenic behaviour.
Being the ﬂexible opportunist that it is, S. aureus is a well-
recognized nosocomial pathogen. Of all nosocomial infections,
S. aureus accounts for approximately 15% [1–4]. This includes
bacteraemia and wound infections, which lead to increased
hospital stay, additional antibiotic use, and elevated costs,
morbidity, and mortality [4–9]. Patients who are nasal carriers
(20–50%) are at increased risk of developing autoinfection
[8,10–14]. Thus, eradication of S. aureus nasal carriage may
prevent nosocomial infections, and such interventions have
been proven to be clinically effective [8,14–17]. For instance,
mupirocin treatment combined with chlorhexidine washings
was effective in eliminating S. aureus from both the nares and
skin [18,19], which reduced the number of nosocomial S. aureus
endo-infections.
Whether prior nasal colonization with a methicillin-
susceptible S. aureus (MSSA) strain protects against acquisition
of exogeneous MSSA or methicillin-resistant S. aureus (MRSA)
is still largely unknown [20,21]. Consequently, the effect of
prior colonization on S. aureus endo-infection vs. exo-infection
is unclear. It was shown that patients re-admitted to hospital
beneﬁted from a protective effect of being colonized with MSSA
[22,23]. The protective efﬁcacy of such colonization in the
prevention of acquisition of MRSA was calculated to be 78%.
The studies lacked information on real hospital-based events,
including the occurrence of infections, and were considered to
be inconclusive.
In this study, we investigated the frequency of de novo
colonization by S. aureus in patients in a single hospital where a
highly endemic MRSA clone was circulating. We studied
whether patients who carried S. aureus upon admission were
more susceptible to or protected from acquisition of another
S. aureus strain.Materials and methodsStudy design
We performed a single-centre prospective observational
follow-up study. The study involved patients admitted to Hos-
pital Kuala Lumpur (HKL), which is a 2200-bed acute-care and
teaching hospital in Malaysia. The current study covered two
departments: neurosurgery, which has three wards (intensive-
care unit; male ward A; and female ward B); and dermatology.
The majority of the neurosurgery patients were trauma casesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inwithout underlying diseases. Patients in all departments previ-
ously showed a higher rate of S. aureus (MSSA and MRSA)
colonization and infections and more extended hospitalization
periods than patients in other but clinically similar wards (un-
published data). Patients were followed until the moment at
which they left the hospital.
Inclusion criteria
Adult patients (aged 18 years) were included in the study,
after informed consent had been obtained, when the patient
was not pregnant, did not have obvious staphylococcal infection
upon admission, was not hospitalized in the 6 months before,
had a hospital stay of 7 days at the end of the study period,
and provided the possibility of performing frequent microbio-
logical culture. Patients diagnosed with staphylococcal infection
within <24 h after hospitalization were excluded from the
study.
Ethics and informed consent
The study was performed according to the rules of Good
Clinical Practice and according to the Malaysian statutory
deﬁnition of clinical trials. Patients received verbal and written
information on screening for nasal carriage with S. aureus by
nursing personnel. Patients or relatives provided oral consent,
which was noted in the nursing record. Patients had to be
mentally and physically capable of taking the decision to take
part in the study. For patients unable to make such a decision,
guardians were informed, and their initial agreement was ob-
tained. Before ofﬁcial participation, either the patients or their
guardians had to provide ofﬁcial written consent. Patients could
stop participating at any time without having to provide a
particular reason. Furthermore, the study investigator ended
the participation whenever the patient’s wellbeing was
considered to be at risk.
Deﬁnition of staphylococcal carriage state
In the current study, we chose the simplest of carriage deﬁni-
tions: carriers were those subjects who had a positive nasal
culture taken on their admission day (day 1 of hospitalization).
All other patients were deﬁned as non-carriers, irrespective of
whether they had one or more positive cultures for the nasal
swabs taken on days 3, 5 and 7 after admission (Fig. 1). The
likelihood of acquiring one or more new S. aureus strains during
hospitalization in carriers and non-carriers was examined.
Extranasal and nasal S. aureus acquisition
S. aureus isolation from the nose at >48 h after hospitalization
and acquisition of a strain with a different spa type among non-
carriers was considered to be proof of de novo nasal acquisition.
To determine acquisition of S. aureus during hospital stay, datafectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e1–998.e7
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FIG. 1. Nasal cultivation results. ‘No. of
cases’ shows the number of patients who
showed the same sequence of culture pos-
itivity as highlighted in yellow on the right.
‘Cases with similar strains isolated on
different days’ shows only the number of
patients in whom all of the strains were
genetically indistinguishable. NP, not
possible to take swabs; P, positive nasal
culture; – , negative nasal culture.
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by evaluation of patients’ microbiological culture data and by
consulting their physicians and their medical records. Swabs for
MSSA and MRSA cultures were taken twice weekly in cases of
suspicion of infection. Usually, a tracheal swab and/or a urine
specimen were taken for such monitoring. Infections were
retrospectively deﬁned according to the CDC/NHSN Surveil-
lance Deﬁnitions for Speciﬁc Types of Infections (Version
January 2015, as modiﬁed in April 2015). In the case of acqui-
sition of more than one S. aureus strain (both MSSA and MRSA),
the ﬁrst acquired strain was included in the statistical and
epidemiological analyses. A strain with the same spa type found
at additional body sites was considered to be of endogenous
origin, i.e. the same as the nasal isolate cultured on the
admission day (day 1). Isolation of a different spa type from
another body site was considered to be an exogenous acqui-
sition event.
Nasal swabs
Nasal swabs were taken on days 1, 3, 5 and 7 of hospitalization
by trained healthcare personnel. A sterile Transswab (Medical
Wire and Equipment, England, UK) was rotated four times in
both anterior nasal vestibules. The swab was immersed in
0.5 mL of transport medium, and was transported to the
research laboratory of the Department of Medical Microbi-
ology, University Putra Malaysia, together with the patient’s
informed consent form. The swabs were plated on mannitol saltClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectagar (Merck, Selangor, Malaysia) and Chrome Agar for S. aureus
isolation (Becton Dickinson, Sparks, MD, USA) within 6 h of
collection. All cultures that were negative after 48 h at 37°C
were incubated for an additional 5 days at room temperature
until a ﬁnal review. A single colony of the culture-positive Petri
dishes was subjected to Gram staining, catalase testing and
coagulase tube testing to conﬁrm the presence of S. aureus.
Strains were stored at –70°C in LB broth (Merck) with 20%
glycerol. Isolates from potentially MRSA-infected or MSSA-
infected patients were also collected and stored at –70°C. All
isolates were subjected to Sa442 PCR for deﬁnitive species
conﬁrmation [24]. MRSA screening was performed with a
cefoxitin disk diffusion test on a Mueller–Hinton agar plate.
Whenever resistance to cefoxitin (inhibition zone of 21 mm)
was observed, MRSA status was conﬁrmed by PCR of the mecA
gene [25].
Staphylococcal genotyping
All strains collected during the present study were subjected to
genotyping. Chromosomal DNA was extracted with the
DNeasy Kit (QIAGEN Biotechnology Malaysia Sdn Bhd, Kuala
Lumpur, Malaysia), according to the manufacturer’s in-
structions, and spa typing was performed [26]. The ampliﬁed
spa gene fragment was puriﬁed and sequenced, and spa types
were assigned by use of the Spa-server (Ridom, Würzburg,
Germany) [27]. SCCmec typing of MRSA strains was performed
as described previously [25]. Strains that were non-typeable forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e1–998.e7
TABLE 1. Demographic data and carriage status of participating patients
Patient Gender, no. (%)
Age (years), median (mean)
Ethnic background, no. (%) Department, no. (%)
Group No. (%) Male Female Malay Chinese Indian Others NS Dermatology
Carrier 67 (22) 39 (58.2) 28 (41.8) 45 (45.6) 36 (53) 16 (23.8) 9 (13.4) 6 (9) 42 (62.7) 25 (37.3)
Non-carrier 238 (78) 161 (67.6) 77 (32.4) 49 (48.6) 125 (47) 59 (76.2) 31 (86.6) 23 (91) 218 (37.3) 20 (62.7)
Total 305 (100) 200 (65.6) 105 (34.4) 49 (47.8) 161 (52.8) 75 (24.6) 40 (13.1) 29 (9.5) 260 (85.2) 45 (14.8)
Note that the median age for the entire group would be 49.0 years.
NS, neurosurgery.
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of sequence types (STs) of MSSA and MRSA. STs and clonal
clusters were assigned by use of the S. aureus multilocus
sequence typing database (www.mlst.net) hosted by Imperial
College in London, UK.
Statistics
Relative risks with CIs not containing unity were considered to
be signiﬁcant. Differences per group in duration of hospitali-
zation and time to infection were tested for signiﬁcance with
the independent t-test and the Mann–Whitney U-test, based on
the result of a normality test. p-Values of <0.05 were consid-
ered to be signiﬁcant.ResultsPatients and carriage characteristics
The inclusion period was from 16 May 2011 to 16 February
2012, and 342 patients were included. Among them, 37 were
excluded because they were hospitalized for <7 days. In the
end, we included 305 patients in the ﬁnal cohort (260 neuro-
surgery patients and 45 dermatology patients). According to
the three major ethnic groups in Malaysia, participants were
Malay (n = 161, 52.8%), Chinese (n = 75, 24.6%), Indian (n = 40,
13.1%), or ‘other’ (n = 29, 9.5%). The male/female ratio was
65.6%/34.4%. The median age of the patients was 49.0 years
(range, 18–89 years). Rates of carriage were not signiﬁcantlyTABLE 2. Distribution of carriers (methicillin-susceptible Staphyloco
and source of acquired S. aureus strains among patients from differ
Ward
Presence of S. aureus on body sites than the nose, detected dur
MSSA and MRSA MSSA
Presence (n [ 79) Acquisition (n [
Same type as in nose on day
1 Acquired Carrier
Same type as in
1
Neurosurgery, no. 6 59 42 6
Dermatology, no. 5 9 21 4
Total, no. (%) 11 (3.6) 68 (20) 63 10 (18.9)
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Indifferent between ethnic groups (Table 1; chi-square p > 0.05
for all combinations). Carriage among dermatology patients was
signiﬁcantly higher than among neurosurgery patients (62.6% vs.
37.3%, p < 0.05), and all MRSA carriers were detected among
dermatology patients (Table 2). Among the 305 participants, 67
(22%) were identiﬁed as carriers, and 238 (78%) were classiﬁed
as non-carriers. The acquisition rate for new strains was not
different between the neurosurgery and the dermatology
groups (65/260 vs. 14/45 (p 0.245, Fisher exact test), respec-
tively). For this reason, we decided to analyse the group as a
whole without subanalyses for the two different departments.
Among the carriers, 63 (20.1%) carried MSSA and four (1.9%)
carried MRSA (Tables 1 and 2). The average length of stay in the
hospital was 16.2 days.
Strain typing
Three hundred and seventy-six strains were isolated from 135
patients. Among these strains, 263 were of nasal origin, and 113
were from extranasal sites. Overall, we identiﬁed 73 different
spa types. Among these were ten new spa types and two new
STs, which have been deposited in the relevant databases
(Ridom and www.mlst.net). In 34 of the 67 nasal carriers, all
nasal strains isolated on different days shared the same spa type
(Fig. 1). Two different spa types were obtained from 16 pa-
tients, and three different spa types were obtained from four
patients. During the week of nasal screening, 57 acquisitions of
strains with new spa types were detected. The highest rate of
nasal acquisition was documented on day 3 after admissionccus aureus (MSSA) and methicillin-resistant S. aureus (MRSA))
ent wards
ing the follow-up period
MRSA
53) Acquisition (n [ 26)
nose on day
Exogenous Carrier
Same type as in nose on day
1 Exogenous
40 0 0 19
3 4 1 6
43 (81.1) 4 1 (3.9) 25 (96.1)
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FIG. 2. Nasal acquisition day among carriers and non-carriers.
998.e5 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMI(n = 33). We found 18 acquisitions on day 5, and 13 acquisitions
on day 7 (Fig. 2).
Among the six MRSA strains isolated from the anterior nares
of dermatology patients, four were typed as t37/ST239/
SCCmecIII, and other two strains were typed as t421/ST239/
SCCmecIII and t10562/ST573/SCCmecV. The three MRSA
strains isolated from neurosurgery patients shared the same
genotype, and were typed as t37/ST239/SCCmecIII. Spa and
SCCmec typing of acquired MRSA strains (n = 26) revealed t37/
ST239/SCCmecIII (n = 21, 80.7%), t4184/ST22/SCCmecIVh
(n = 4, 15.5%), and t10562/ST573/SCCmecV (n = 1, 4%). Spa
type t10562 was acquired by a dermatology patient, whereas
t4184 strains were detected among inpatients in the neuro-
surgery wards only.
Frequency and sites of acquisition
During the study period, 101 study cases acquired S. aureus, and
the risk of acquisition among carriers was signiﬁcantly higher
than that among non-carriers (p 0.005). According to culture
and typing results, the 101 patients (32 carriers and 69 non-
carriers) acquired one or more strains in their nose or other
body sites during hospital stay (57 and 72 isolates, respectively).
Among them were 82 MSSA and 34 MRSA acquisitions
(Table 3). The majority of the strains cultured from clinicalTABLE 3. Comparison of risk of acquiring methicillin-susceptible S
(MRSA) in nasal carriers vs. non-carriers
Carrier deﬁnition Patient category
MSSA and MRSA
acquisition (no.)
Positive Negative
Based on ﬁrst-day nasal swab results Carrier (n = 67) 32 35
Non-carrier (n = 238) 69 169
Total (n = 305) 101 204
p 0.005a
Bold type indicates statistical signiﬁcance.
aFisher exact test.
bMann–Whitney U-test.
cIndependent t-test.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectsamples (n = 60, 51.7%) were isolated from tracheal aspirates
(49 MSSA and 11 MRSA). Fifty-two strains (44.8%) were iso-
lated from the nose (44 MSSA and eight MRSA), 18 strains
(15.5%) were isolated from pus (eight MSSA and ten MRSA),
and three strains were isolated from blood cultures (one MSSA
and two MRSA). Another two strains were isolated from urine
(one MSSA and one MRSA), and the ﬁnal MRSA strain was
isolated from a wound (Fig. 3).
Endogenous vs. exogenous events
When nasal acquisition was excluded, 53 MSSA acquisitions at
alternative body sites were detected in the study group: 46 in
neurosurgery patients, and seven in dermatology patients
(Table 2). Twenty-six MRSA acquisitions were noted: 19 in
neurosurgery patients, and seven in dermatology patients. Com-
parison of the spa types of the MSSA and MRSA strains isolated
from the alternative body sites with the nasal isolates (on day of
admission) revealed an endogenous origin of 11 strains (tenMSSA
and one MRSA), and an exogenous origin of 68 strains (43 MSSA
and 25 MRSA) (Table 2). Among 42 MSSA carriers in the
neurosurgery ward, six were colonized with an MSSA strain
sharing the same spa type; and among 21 MSSA carriers in the
dermatology ward, four had endogenous MSSA cultured
(Table 2).One of fourMRSA carriers among dermatology patients
harboured the same strain as the one isolated from the anterior
nares in an extranasal site. Ten of 63 MSSA carriers acquired a
strain with a similar spa type as the one from their anterior nares
in an extranasal site. The majority of MSSA (81.1%) and MRSA
(96.1%) acquisitions were of exogenous origin (Table 2).
S. aureus acquisition among carriers vs. non-carriers
Among the patients, 82 MSSA acquisitions were documented:
26 among carriers, and 59 among non-carriers (Table 3).
Thirty-four MRSA acquisitions were documented: eight among
carriers, and 26 among non-carriers. There was a signiﬁcant
difference between carriers and non-carriers MSSA acquisitiontaphylococcus aureus (MSSA) or methicillin-resistant S. aureus
MSSA acquisition
(no.)
MRSA acquisition
(no.)
Start day of
acquisition (mean
days)
Positive Negative Positive Negative MSSA MRSA
26 41 8 59 2.8 5.1
59 182 26 212 7 22
82 223 34 271 5.7 17.4
p 0.019a p 0.827a p 0.142b p 0.012c
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e1–998.e7
FIG. 3. Sites of acquisition of different Staphylococcus aureus strains.
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible
S. aureus.
CMI Ghasemzadeh-Moghaddam et al. Nasal carriers more likely to acquire exogenous Staphylococcus aureus 998.e6(p 0.019) during hospitalization, whereas no difference was
observed for MRSA acquisition (p = 0.827). However, carriers
acquired MRSA faster than non-carriers (mean of 5.1 days vs.
mean of 22 days, respectively) (t26 = 2.893, p 0.012). No sig-
niﬁcant difference was observed for time between admission
and day of MSSA acquisition among carriers (mean of 2.8 days)
vs. non-carriers (mean of 7 days) (Table 3).DiscussionColonization by S. aureus is a multifactorial process, with both
host and bacterial factors being involved. It is not well known
whether or not the prior presence of an S. aureus strain pre-
disposes to or protects against colonization by a new strain.
Precisely tuned natural human (re)colonization schemes are not
available [28,29], although it has been demonstrated previously
that persistent carriers can change their nasal strain over time
while staying phenotypically persistent carriers [30]. In this
study, we have demonstrated that existing nasal carriage of
S. aureus is a signiﬁcant determinant for acquiring new S. aureus
strains, which is in contrast to previous data [23].
A 33.7% MRSA carriage rate was reported previously for
HKL patients [31,32]. Previous investigations on the predomi-
nant MRSA lineages in HKL revealed that ST239/SCCmecIII or
ST239/SCCmecIIIa (92.5%) and ST22/SCCmecIVh (1.5%) are
the most successful lineages isolated from infection sites [33].
The majority of the MRSA infections (92.5%) among patients in
the current study were also caused by ST239 MRSA strains.
This ﬁnding shows that being a nasal carrier of S. aureus is not
protective against the acquisition of MRSA strains circulating in
the environment, although antibiotic usage may be inﬂuential.
Unfortunately, we lack data on antibiotic usage, but, given the
lack of precise antibiotic policies in the hospital concerned, we
assume that, during the present study, this was sufﬁciently
randomized. The variable genotypes of the MSSA strainsClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inisolated from the nose and/or body sites was in concordance
with the results of previous studies [34,35].
It has been shown recently that nosocomial acquisition of
MRSA results in morbidity and mortality upon re-admission of
elderly persons to the hospital [36]. This suggests that screening
for MRSA acquisition and management of its risks is clinically
important. We conclude that nasal carriage of S. aureus pre-
disposes to nosocomial acquisition of new strains, both in the
nose and in extranasal body sites. It has been shown that resident
populations of S. aureus may be heterogeneous, with multiple
genotypes being present simultaneously. Our current data are
unlikely to be confounded by such phenomena, as we only used
culture positivity as a single marker for carriage. Strain hetero-
geneity or mixed colonization, for instance, would not affect this
type of purely numerical and statistical analysis. However, there
are some inherent weaknesses in the design of our study. Major
weaknesses that need to be taken into account are the fact that
the ﬁrst nasal culture may be falsely negative or that there may be
a strong correlation between cross-colonization and the local
level of hygiene practices. We were also unable to include throat
and perianal cultures in order to screen for secondary carriage of
S. aureus at these alternative anatomical sites. Second, because
prospective studies are very difﬁcult in our ﬁeld of study, we had
to use a simpliﬁed test for deﬁnition of carriage, and not repetitive
serial culture [29]. In any case, our ﬁndings again underscore the
relevance of regular sampling of the nasal cavity of patients,
especially those who were previously identiﬁed as persistent
carriers, in order to continuously minimize risks. In addition, it
demonstrates that being a non-carrier in a hospital setting has a
protective effect that is probably purely host deﬁned. Investiga-
tion into this protective effect may reveal novel methods for
protecting patients from staphylococcal disease.Transparency declarationThe authors declare no conﬂicts of interest in relation to the
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